Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.34 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.34 |
| ▸ | CETP | P11597 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19450522 | 0.81 | NPC1 (0.48) | ACACBNPC1RAB9AKDM4EGPR119 | |
| SCHEMBL19450528 | 0.80 | OGA (0.43) | ACACBGPR119TIPARPPPARGPPARD | |
| SCHEMBL19457346 | 0.77 | GPR119 (0.39) | ACACBGPR119TIPARPCETP | |
| SCHEMBL19457229 | 0.72 | GPR119 (0.38) | ACACBNPC1RAB9AKDM4EGPR119 | |
| SCHEMBL22878533 | 0.71 | GPR119 (0.44) | ACACBGPR119TIPARPPPARGPPARD | |
| SCHEMBL19449869 | 0.71 | NPC1 (0.51) | ACACBNPC1RAB9AKDM4EGPR119 | |
| SCHEMBL19457343 | 0.71 | OGA (0.44) | ACACBGPR119TIPARP | |
| SCHEMBL20969505 | 0.71 | NPC1 (0.51) | ACACBNPC1RAB9AKDM4EGPR119 | |
| SCHEMBL19454610 | 0.71 | NPC1 (0.51) | ACACBNPC1RAB9AKDM4EGPR119 | |
| SCHEMBL19450531 | 0.68 | KDM4E (0.54) | ACACBNPC1RAB9AKDM4EGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208030-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | ACACB 2715/4885NPC1 842/4885RAB9A 854/4885 |
| US-10208030-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | ACACB 2102/4885NPC1 685/4885RAB9A 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.